Benitec Biopharma Inc. (BNTC)
Stock Price:
$8.31 USD
0.00 (0.00%)
Updated Aug 13, 2020 4:00 PM EDT - Market open
Key Info
| Market Cap |
13.35M |
| Revenue (ttm) |
11.55M |
| Net Income (ttm) |
2.93M |
| Shares Out |
1.07M |
| EPS (ttm) |
-0.82 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 13, 2020 |
| Last Price |
$8.31 |
| Previous Close |
$8.31 |
| Change ($) |
0.00 |
| Change (%) |
0.00% |
| Day's Open |
- |
| Day's Range |
8.10 - 8.75 |
| Day's Volume |
0 |
| 52-Week Range |
4.14 - 19.80 |
More Stats
| Market Cap |
13.35M |
| Enterprise Value |
-2.80M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
1.07M |
| Float |
752,368 |
| EPS (basic) |
n/a |
| EPS (diluted) |
-0.82 |
| FCF / Share |
2.94 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
28.32% |
| Payout Ratio |
n/a |
| Shares Short |
3,629 |
| Short Ratio |
0.50 |
| Short % of Float |
0.70% |
| Beta |
1.94 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
3.53 |
| PS Ratio |
1.16 |
| PB Ratio |
162.35 |
| Revenue |
11.55M |
| Operating Income |
1.94M |
| Net Income |
2.93M |
| Free Cash Flow |
3.78M |
| Net Cash |
16.15M |
| Net Cash / Share |
10.05 |
| Gross Margin |
100.00% |
| Operating Margin |
16.76% |
| Profit Margin |
25.30% |
| FCF Margin |
32.72% |
| ROA |
-21.76% |
| ROE |
-38.83% |
| ROIC |
n/a |
Key stats in USD, based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (1)
| Buy |
1 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
14.0
Current: $8.31
High
14.0
Target: 14.00
*Average 12-month USD price target from 1 stock analysts.
Financial Performance
Financial numbers in millions AUD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|
| Revenue | 16.16 | 0.38 | 0.33 | 0.46 | 1.08 | 0.60 |
| Revenue Growth | 4174.87% | 13.51% | -28.23% | -57.08% | 80.77% | - |
| Gross Profit | 16.16 | 0.38 | 0.33 | 0.46 | 1.08 | 0.60 |
| Operating Income | 2.71 | -15.88 | -16.18 | -27.95 | -14.40 | -7.38 |
| Net Income | 4.09 | -11.64 | -5.69 | -24.78 | -11.51 | -7.04 |
| Shares Outstanding | 25.70 | 20.51 | 14.65 | 11.59 | 11.59 | - |
| Earnings Per Share | 3.18 | -11.06 | -6.48 | -34.82 | -19.92 | -15.56 |
| Operating Cash Flow | 5.86 | -9.79 | -8.30 | -20.21 | -9.69 | -9.27 |
| Capital Expenditures | -0.57 | -0.08 | -0.17 | -0.34 | -0.51 | -0.03 |
| Free Cash Flow | 5.29 | -9.88 | -8.48 | -20.55 | -10.20 | -9.30 |
| Cash & Equivalents | 22.59 | 16.22 | 17.48 | 18.26 | 21.79 | 31.36 |
| Net Cash / Debt | 22.59 | 16.22 | 17.48 | 18.26 | 21.79 | 31.36 |
| Assets | 27.43 | 21.34 | 22.67 | 19.89 | 25.52 | 34.50 |
| Liabilities | 3.77 | 2.60 | 1.16 | 1.05 | 1.64 | 0.96 |
| Book Value | 23.66 | 18.74 | 21.51 | 18.84 | 23.88 | 33.54 |
Numbers in millions AUD, except per-share numbers.
Company Details
| Full Name |
Benitec Biopharma Inc. |
| Country |
United States |
| CEO |
Jerel A. Banks |
Stock Information
| Ticker Symbol |
BNTC |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: BNTC |
Description
Benitec Biopharma, Inc., a development-stage biotechnology company, focuses on the advancement of novel genetic medicines. Its proprietary silence and replace approach combines DNA-directed RNA interference with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration. The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions, including oculopharyngeal muscular dystrophy (OPMD), and chronic hepatitis B. The company was founded in 1995 and is based in Hayward, California.